Bone Therapeutics publishes results of ALLOB Phase I/IIa study for the treatment of delayed-union fractures in Stem Cell Research & Therapy

NEXT STORY
OSE Immunotherapeutics Announces Manufacturing Agreement with Cenexi for Clinical Batches of CoVepiT, OSE’s Multi-Target Second-Generation COVID-19 Vaccine
PREV STORY
AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for 9 Targeted Therapies for Use in Patients with Advanced Non-Small Cell Lung Cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Bone Therapeutics publishes results of ALLOB Phase I/IIa study for the treatment of delayed-union fractures in Stem Cell Research & Therapy

NEXT STORY
OSE Immunotherapeutics Announces Manufacturing Agreement with Cenexi for Clinical Batches of CoVepiT, OSE’s Multi-Target Second-Generation COVID-19 Vaccine
PREV STORY
AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for 9 Targeted Therapies for Use in Patients with Advanced Non-Small Cell Lung Cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

First Watch Restaurant Group, Inc. Announces Preliminary Operational Metrics

author_avatar
NASDAQ Market News

Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2017 Financial Results and Business Update

Company Preparing for Potential Commercial Launch of AZEDRA® (iobenguane I 131) Ahead of U.S. ...

author_avatar
NASDAQ Market News

Global cephalosporin drugs market is expected to grow with a CAGR of 3.5% over the forecast period from 2019-2025

author_avatar
NASDAQ Market News